The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
About the show
Latest episodes
-
ArriVent’s Lung Cancer Pill Hits Setback & Alector’s $100M Genentech Deal
October 7, 2026 · 8 minArriVent's firmonertinib missed its Phase 3 primary progression-free-survival endpoint in lung cancer, with its next step still undecided; this delayed Tuesday edition was recorded October 6. Alector grants Genentech worldwide rights to…
-
EASD 2026 Debrief: Type 2 Diabetes Care Moves Earlier & Foundayo Meets a Heart-Safety Bar
October 6, 2026 · 17 minThe Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and payer strategy. The new ADA/EASD consensus reportmoves GLP-1 and SGLT2…
-
Daily Roundup | Genmab's Epkinly Wins Frontline Trial & Vaxcyte's Vaccine Passes With Caveats
October 6, 2026 · 8 minGenmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of 3–5; it did not face Polivy's approved regimen. Vaxcyte's VAX-31 met…
-
Week in Review | Lilly's Retatrutide Dose Data, Novartis' RNA Deal & Jaypirca's Approval
October 5, 2026 · 47 minLilly's retatrutide detail reveals that adverse-event discontinuations peaked below the top dose, while Jaypirca gains first-line CLL and SLL approval for adults without a known 17p deletion. Novartis agrees to $575 million upfront for…
-
ASTRO 2026 Debrief: Who Still Needs Hormone Therapy & Protons vs Photons in Liver Cancer
October 4, 2026 · 26 minThe Pharma Closeout's ASTRO 2026 Debrief covers the readouts from the American Society for Radiation Oncology meeting that matter for drug,diagnostic and payer strategy. Fourteen-year RTOG 0815 data re-open how much hormone therapy men…
-
Daily Roundup | Jaypirca Adds a First-Line CLL Choice & Novartis Signs $575M Abogen License
October 3, 2026 · 9 minDelayed Friday edition, recorded October 2. Lilly's Jaypirca (pirtobrutinib) gains first-line approval for adults with CLL/SLL without a known 17p deletion—but how does a trial against older chemotherapy guide today's treatment choice?…
-
Survodutide Phase 3 Comes With GI Tolerability Cost & Trevogrumab Trims Lean-Tissue Loss on Scans
October 2, 2026 · 9 minBoehringer's survodutide reached up to 13.1% weight loss in Phase 3 assuming patients stayed on treatment, but GI-related dropouts complicate its place in obesity and Type 2 diabetes. CMS's final GLOBE rule tests international prices in…
-
Daily Roundup | Lilly's amylin add-on brings more weight loss and more dropouts & Rafael plans NDA after NPC miss
October 1, 2026 · 12 minSeptember 30 edition, released October 1. Date references in the audio are anchored to September 30. Lilly's EloraTZP (eloralintide plus tirzepatide) reached 23.3% weight loss vs 14.8% for tirzepatide in a secondary Phase 2b comparison…